These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6702555)

  • 1. The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis.
    Shea MJ; Driscoll EM; Romson JL; Pitt B; Lucchesi BR
    Am Heart J; 1984 Apr; 107(4):629-37. PubMed ID: 6702555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of oral nafazatrom (= BAY g 6575) on canine coronary artery thrombosis and myocardial ischemia.
    Fiedler VB
    Basic Res Cardiol; 1983; 78(3):266-80. PubMed ID: 6615399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of nafazatrom on ischemic reperfused myocardium.
    Shea MJ; Murtagh JJ; Jolly SR; Abrams GD; Pitt B; Lucchesi BR
    Eur J Pharmacol; 1984 Jun; 102(1):63-70. PubMed ID: 6479219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
    Bednar M; Smith B; Pinto A; Mullane KM
    Circ Res; 1985 Jul; 57(1):131-41. PubMed ID: 2988818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.
    Fiedler VB; Mardin M; Perzborn E; Grützmann R
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):267-74. PubMed ID: 3841382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog.
    Fiedler VB; Mardin M
    J Cardiovasc Pharmacol; 1985; 7(5):983-9. PubMed ID: 2413312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of zomepirac on experimental coronary artery thrombosis and ischemic myocardial injury in the conscious dog.
    Hook BG; Romson JL; Jolly SR; Bailie MB; Lucchesi BR
    J Cardiovasc Pharmacol; 1983; 5(2):302-8. PubMed ID: 6188907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of arterial thrombosis and platelet function by nafazatrom.
    Buchanan MR; Blajchman M; Hirsh J
    Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of occlusive coronary artery thrombosis and myocardial ischemia by molsidomine in anesthetized dogs.
    Fiedler VB
    Can J Physiol Pharmacol; 1982 Aug; 60(8):1104-11. PubMed ID: 6897011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease.
    Roy L; Mehta J; Mehta P
    Am Heart J; 1985 May; 109(5 Pt 1):1026-31. PubMed ID: 3158183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of acute myocardial ischemia in rabbit hearts by nafazatrom.
    Fiedler VB
    J Cardiovasc Pharmacol; 1984; 6(2):318-24. PubMed ID: 6200722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog.
    Shea MJ; Driscoll EM; Romson JL; Pitt B; Lucchesi BR
    Eur J Pharmacol; 1984 Oct; 105(3-4):285-91. PubMed ID: 6542526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition by AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonyl methoxy coumarin) of platelet aggregation in dog stenosed coronary artery.
    Prosdocimi M; Finesso M; Tessari F; Gorio A; Languino LR; de Gaetano G; Dejana E
    Thromb Res; 1985 Aug; 39(4):399-409. PubMed ID: 3840290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog.
    Cousins GR; Friedrichs GS; Sudo Y; Rebello SS; Rote WE; Vlasuk GP; Nolan TG; Mendoza C; Lucchesi BR
    Circulation; 1996 Oct; 94(7):1705-12. PubMed ID: 8840864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic effects of BMY21190, an inhibitor of cAMP phosphodiesterase, in a canine model of coronary artery thrombosis.
    Minami M; Driscoll EM; Lucchesi BR
    Jpn Circ J; 1993 Oct; 57(10):979-92. PubMed ID: 8230679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of nafazatrom to reduce infarct size and arrhythmias in a porcine model of acute coronary occlusion.
    Fiedler VB
    Eur J Pharmacol; 1985 Aug; 114(2):189-95. PubMed ID: 3930268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
    Coker SJ; Parratt JR
    J Mol Cell Cardiol; 1984 Jan; 16(1):43-52. PubMed ID: 6366241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation.
    Benedict CR; Mathew B; Rex KA; Cartwright J; Sordahl LA
    Circ Res; 1986 Jan; 58(1):58-67. PubMed ID: 3943156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.